Top

Published in:

01-02-2015 | Research Article

Lactotransferrin could be a novel independent molecular prognosticator of nasopharyngeal carcinoma

Authors: Wenling Zhang, Songqing Fan, Guoying Zou, Lei Shi, Zhaoyang Zeng, Jian Ma, Yanhong Zhou, Xiayu Li, Xinlin Zhang, Xiaoling Li, Ming Tan, Wei Xiong, Guiyuan Li

Published in: Tumor Biology | Issue 2/2015

Abstract

Lactotransferrin (LTF), also known as lactoferrin, is a key component of innate immune defense. We previously reported that LTF was downregulated in nasopharyngeal carcinoma (NPC) and could suppress NPC cell proliferation. However, the relevance of the relationship between LTF expression and NPC clinical outcome has not been reported. This study aims to assess the possible correlations between LTF expression and clinical parameters and its potential prognostic predictive ability in the outcomes of patients with NPC. Complementary DNA (cDNA) microarray, quantitative real-time PCR (qRT-PCR), and immunohistochemistry (IHC) results suggested that LTF expression was significantly downregulated in NPC tissues compared to non-NPC tissues. LTF was negatively correlated with lymph node metastasis (P = 0.042), T stage (P < 0.001), clinical tumor-node-metastasis (TNM) stage (P = 0.022), and EBV-encoded RNA 1 (EBER-1) expression (r = −.167, P = 0.016). A survival analysis of 108 patients with NPC revealed that positive expression of LTF could predict a good prognosis [disease-free survival (DFS): P = 0.043, overall survival (OS): P = 0.040]. Multivariable analysis revealed that LTF could independently predict prognosis (DFS: HR = 0.414, P = 0.003; OS: HR = 0.309, P = 0.005). These observations indicated that LTF is a potential prognostic factor of NPC.

Available only for authorised users

Alexander DB, Iigo M, Yamauchi K, Suzui M, Tsuda H. Lactoferrin: an alternative view of its role in human biological fluids. Biochem Cell Biol. 2012;90:279–306.CrossRefPubMed

Gonzalez-Chavez SA, Arevalo-Gallegos S, Rascon-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents. 2009;33:301.CrossRefPubMed

Legrand D, Mazurier J. A critical review of the roles of host lactoferrin in immunity. Biometals. 2010;23:365–76.CrossRefPubMed

Rodrigues L, Teixeira J, Schmitt F, Paulsson M, Mansson HL. Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr. 2009;49:203–17.CrossRefPubMed

Ward PP, Paz E, Conneely OM. Multifunctional roles of lactoferrin. A critical overview. Cell Mol Life Sci. 2005;62:2540–8.CrossRefPubMed

Huang HB, Deng M, Zheng Y, Ma J, Zhang WL, Zhou YH, et al. Innate immune protein lactotransferrin prevents initiation and arrests progression of nasopharyngeal carcinoma. Prog Biochem Biophys. 2013;40:319–24.

Li WY, Li QW, Han ZS, Jiang ZL, Yang H, Li J, et al. Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm. 2011;26:477–83.CrossRefPubMed

Yi HM, Li H, Peng D, Zhang HJ, Wang L, Zhao M, et al. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. Oncol Res. 2006;16:261–72.PubMed

Kholodnyuk ID, Kozireva S, Kost-Alimova M, Kashuba V, Klein G, Imreh S. Down regulation of 3p genes, LTF, SLC38A3 and DRR1, upon growth of human chromosome 3-mouse fibrosarcoma hybrids in severe combined immunodeficiency mice. Int J Cancer. 2006;119:99–107.CrossRefPubMed

10.

Yang Y, Li J, Szeles A, Imreh MP, Kost-Alimova M, Kiss H, et al. Consistent downregulation of human lactoferrin gene, in the common eliminated region 1 on 3p21.3, following tumor growth in severe combined immunodeficient (SCID) mice. Cancer Lett. 2003;191:155–64.CrossRefPubMed

11.

Xiao Y, Monitto CL, Minhas KM, Sidransky D. Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res. 2004;10:8683–6.CrossRefPubMed

12.

Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, Tan Y, et al. Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer. 2008;123:2065–72.CrossRefPubMed

13.

Deng M, Zhang W, Tang H, Ye Q, Liao Q, Zhou Y, et al. Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene. 2013;32:4273–83.CrossRefPubMed

14.

Zeng Z, Zhou Y, Xiong W, Luo X, Zhang W, Li X, et al. Analysis of gene expression identifies candidate molecular markers in nasopharyngeal carcinoma using microdissection and cDNA microarray. J Cancer Res Clin Oncol. 2007;133:71–81.CrossRefPubMed

15.

Zeng ZY, Zhou YH, Zhang WL, Xiong W, Fan SQ, Li XL, et al. Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol. 2007;38:120–33.CrossRefPubMed

16.

Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene. 2003;22:6497–507.CrossRefPubMed

17.

Hoheisel JD. Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet. 2006;7:200–10.CrossRefPubMed

18.

Zeng Z, Huang H, Zhang W, Xiang B, Zhou M, Zhou Y, et al. Nasopharyngeal carcinoma: advances in genomics and molecular genetics. Sci China Life Sci. 2011;54:966–75.CrossRefPubMed

19.

Liao Q, Zeng Z, Guo X, Li X, Wei F, Zhang W, et al. LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation. Oncogene. 2014;33:2098–109.CrossRefPubMed

20.

Yang Y, Liao Q, Wei F, Li X, Zhang W, Fan S, et al. LPLUNC1 inhibits nasopharyngeal carcinoma cell growth via down-regulation of the MAP kinase and cyclin D1/E2F pathways. PLoS One. 2013;8:e62869.CrossRefPubMedPubMedCentral

21.

Zhang W, Zeng Z, Wei F, Chen P, Schmitt DC, Fan S, et al. SPLUNC1 is associated with nasopharyngeal carcinoma prognosis and plays an important role in ATRA-induced growth inhibition and differentiation in nasopharyngeal cancer cells. FEBS J. 2014. doi:10.1111/febs.13020.

22.

Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–7.CrossRefPubMed

23.

Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845–56.CrossRefPubMed

24.

Sriuranpong V, Mutirangura A, Gillespie JW, Patel V, Amornphimoltham P, Molinolo AA, et al. Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays. Clin Cancer Res. 2004;10:4944–58.CrossRefPubMed

25.

Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, Chen M, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 2006;66:7999–8006.CrossRefPubMed

26.

Tang K, Wei F, Bo H, Huang HB, Zhang WL, Gong ZJ, et al. Cloning and functional characterization of a novel long non-coding RNA gene associated with hepatocellular carcinoma. Prog Biochem Biophys. 2014;41:153–62.

27.

Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005;65:767–79.PubMed

28.

Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112:4235–46.CrossRefPubMedPubMedCentral

29.

Fan SQ, Ma J, Zhou J, Xiong W, Xiao BY, Zhang WL, et al. Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis. Hum Pathol. 2006;37:593–605.CrossRefPubMed

30.

Zhang W, Zeng Z, Fan S, Wang J, Yang J, Zhou Y, et al. Evaluation of the prognostic value of TGF-beta superfamily type I receptor and TGF-beta type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays. J Mol Histol. 2012;43:297–306.CrossRefPubMed

31.

Zhang W, Huang C, Gong Z, Zhao Y, Tang K, Li X, et al. Expression of LINC00312, a long intergenic non-coding RNA, is negatively correlated with tumor size but positively correlated with lymph node metastasis in nasopharyngeal carcinoma. J Mol Histol. 2013;44:545–54.CrossRefPubMed

32.

Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249–56.CrossRefPubMedPubMedCentral

33.

van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK. Antiviral activities of lactoferrin. Antiviral Res. 2001;52:225–39.CrossRefPubMed

34.

Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR, Li XL, et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res. 2004;64:1972–4.CrossRefPubMed

35.

Zeng Z, Zhou Y, Zhang W, Li X, Xiong W, Liu H, et al. Family-based association analysis validates chromosome 3p21 as a putative nasopharyngeal carcinoma susceptibility locus. Genet Med. 2006;8:156–60.CrossRefPubMed

36.

Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, Roy B, et al. Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: correlation with progression and prognosis. Int J Cancer. 2008;123:2594–604.CrossRefPubMed

37.

Gong ZJ, Huang HB, Xu K, Liang F, Li XL, Zeng ZY, et al. Advances in microRNAs and TP53 gene regulatory network. Prog Biochem Biophys. 2012;39:1133–44.CrossRef

38.

Deng M, Ye Q, Qin Z, Zheng Y, He W, Tang H, et al. MiR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma. Tumour Biol. 2013;34:1793–800.CrossRefPubMed

39.

Chen P, Guo X, Zhou H, Zhang W, Zeng Z, Liao Q, et al. SPLUNC1 regulates cell progression and apoptosis through the miR-141-PTEN/p27 pathway, but is hindered by LMP1. PLoS One. 2013;8:e56929.CrossRefPubMedPubMedCentral

40.

Zhang W, Zeng Z, Zhou Y, Xiong W, Fan S, Xiao L, et al. Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis. Acta Biochim Biophys Sin (Shanghai). 2009;41:414–28.CrossRef

41.

Zeng Z, Huang H, Huang L, Sun M, Yan Q, Song Y, et al. Regulation network and expression profiles of Epstein-Barr virus-encoded microRNAs and their potential target host genes in nasopharyngeal carcinomas. Sci China Life Sci. 2014;57:315–26.CrossRefPubMed

42.

Gong Z, Zhang S, Zhang W, Huang H, Li Q, Deng H, et al. Long non-coding RNAs in cancer. Sci China Life Sci. 2012;55:1120–4.CrossRefPubMed

43.

Weiss LM, Chen YY. EBER in situ hybridization for Epstein-Barr virus. Methods Mol Biol. 2013;999:223–30.CrossRefPubMed

44.

Wei F, Li XY, Li XL, Zhang WL, Liao QJ, Zeng Y, et al. The effect and mechanism of PLUNC protein family against inflammation and carcinogenesis of nasopharyngeal carcinoma. Prog Biochem Biophys. 2014;41:24–31.

Title: Lactotransferrin could be a novel independent molecular prognosticator of nasopharyngeal carcinoma
Authors: Wenling Zhang
Songqing Fan
Guoying Zou
Lei Shi
Zhaoyang Zeng
Jian Ma
Yanhong Zhou
Xiayu Li
Xinlin Zhang
Xiaoling Li
Ming Tan
Wei Xiong
Guiyuan Li
Publication date: 01-02-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2650-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects

The functional sites of miRNAs and lncRNAs in gastric carcinogenesis

GRP78 mediates the therapeutic efficacy of curcumin on colon cancer

Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer

Clinical utility of certain biomarkers as predictors of breast cancer with or without metastasis among Egyptian females

Crk-like adapter protein is required for TGF-β-induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer